Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Jinhai Medical Technology Limited
今海醫療科技股份有限公司

(Incorporated in the Cayman Islands with members' limited liability)

(Stock Code: 2225)

INSIDE INFORMATION
DISPOSAL OF SHARES BY A CONTROLLING SHAREHOLDER

This announcement is made by Jinhai Medical Technology Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

On 6 November 2026, the Company was informed by Mr. Chen Guobao ("**Mr. Chen**"), the Chairman and the executive director of the Company, and Full Fortune International Co., Ltd ("**Full Fortune**"), a controlling shareholder (as defined under the Listing Rules) of the Company and a company wholly owned by Mr. Chen as at the date of this announcement, that on 6 November 2026, Full Fortune, as the vendor, entered into a sale and purchase agreement (the "**Agreement**") with Mr. Yang Fu Kang ("**Mr. Yang**") (the "**Purchaser**") in relation to the disposal of 1,057,486,000 shares of the Company (the "**Shares**") (representing approximately 19.86% of the entire issued share capital of the Company as at the date of this announcement) to Mr. Yang (the "**Disposal**"). Completion of the Disposal took place after the signing of the Agreement. To the best of the knowledge, information and belief of the directors of the Company, having made all reasonable enquiries, the Purchaser is a third party independent of and not acting in concert with Full Fortune, the Group, or any director, chief executive or substantial shareholder of the Group or any of their respective associates.

Upon completion of the Disposal, the number of Shares held by Full Fortune will decrease from 2,530,000,000 Shares (representing approximately 47.52% of the entire issued share capital of the Company as at the date of this announcement) to 1,472,514,000 Shares (representing approximately 27.66% of the entire issued share capital of the Company as at the date of this announcement). Immediately after completion of the Disposal, (a) Full Fortune will cease to be the controlling shareholder (as defined under the Listing Rules) of the Company; and (b) Mr. Yang will become a substantial shareholder (as defined under the Listing Rules) of the Company, holding approximately 19.86% of the entire issued share capital of the Company as at the date of this announcement.

The Company does not expect that the Disposal will have any material adverse effect on the business operation and financial position of the Company.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Jinhai Medical Technology Limited
Chen Guobao
Chairman of the Board and executive Director

Hong Kong, 6 November 2026

As at the date of this announcement, the Board comprises seven Directors, of which three are executive Directors, namely Mr. Chen Guobao, Mr. Li Bin, and Mr. Wang Zhenfei; one is non-executive Director, namely Mr. Wang Huasheng; and three are independent non-executive Directors, namely Mr. Yan Jianjun, Mr. Fan Yimin, and Ms. Liu Jinjing.